Phaseline

Companies › Excyte Biopharma

Excyte Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Genitourinary, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YK012
Bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediate
CD19, CD3Phase 1Primary Membranous Nephropathy; B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory B-Cell Non-Hodgkin LymphomaDec 2026
YKST02
BCMA-CD3 bispecific antibody
BCMA, CD3EPhase 1Relapsed or Refractory Multiple MyelomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06982729YK012Phase 1Primary Membranous NephropathyGenitourinaryDec 2026
NCT06580301YK012Phase 1B-cell Acute Lymphoblastic LeukemiaOncologyDec 2026
NCT06574568YKST02Phase 1Relapsed or Refractory Multiple MyelomaOncologyDec 2026
NCT07010835YK012Phase 1Systemic Lupus Erythematosus (SLE)ImmunologyJun 2027
NCT06565689YK012Phase 1Relapsed or Refractory B-Cell Non-Hodgkin LymphomaOncologyDec 2028

Targets

CD19 (1) CD3 (1) BCMA (1) CD3E (1)

Companies with the same targets

Chongqing Precision Biotech Johnson & Johnson (Janssen) Gilead Sciences AstraZeneca Bristol-Myers Squibb Kali Therapeutics Roche Amgen iCell Gene Therapeutics Allogene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.